Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million
13 oct. 2020 07h00 HE
|
Eyenovia, Inc.
Company reaffirms near term milestones for the Mydcombi™ (MicroStat) NDA and the MicroLine presbyopia program Phase III results Call scheduled for today, Tuesday, October 13 at 4:30pm ET ...
Eyenovia to Present at the 22nd Annual H.C. Wainwright Global Investment Conference
09 sept. 2020 08h30 HE
|
Eyenovia, Inc.
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia, Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option in Public Offering
24 août 2020 08h30 HE
|
Eyenovia, Inc.
NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia, Inc. Announces Closing of Offering of Common Stock
21 août 2020 16h05 HE
|
Eyenovia, Inc.
NEW YORK, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia, Inc. Prices Public Offering of Common Stock
19 août 2020 09h10 HE
|
Eyenovia, Inc.
NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia, Inc. Announces Proposed Public Offering of Common Stock
18 août 2020 16h03 HE
|
Eyenovia, Inc.
NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia Reports Second Quarter 2020 Financial Results
12 août 2020 16h05 HE
|
Eyenovia, Inc.
NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia and Arctic Vision Announce Exclusive Collaboration and License Agreement to Develop and Commercialize MicroPine and MicroLine in Greater China and South Korea
11 août 2020 08h00 HE
|
Eyenovia, Inc.
Eyenovia Eligible to Receive up to a Total of $45.75 million in Upfront Payments and Development and Commercialization Milestones and Development Costs Arctic Vision to Lead Expansion of Novel...
Eyenovia Announces Conference Call and Webcast for Second Quarter 2020 Financial Results
29 juil. 2020 08h30 HE
|
Eyenovia, Inc.
NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia
30 juin 2020 16h05 HE
|
Eyenovia, Inc.
NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...